ABSTRACT: A novel method was developed and optimized to measure the in vitro release (IVR) of two liposomal ciprofloxacin formulations under development to treat lung infection. The release agent, bovine serum, has components that interact with liposomes to cause the encapsulated drug to be released. The precision and accuracy of the method were characterized. The method has a nearly linear release phase initially, which then approaches a plateau value after 2-4 h. The robustness of the method was verified over a range of release agent and liposomal concentrations, and in response to changes in incubation temperature, buffer pH, and storage containers of serum. For this "sample and separate" IVR method, there is less than 2% release at the T = 0 time point, indicating negligible artifactual release before analysis. For both inhaled liposomal ciprofloxacin products, the plateau value represents 100% release of the encapsulated drug. The key elements of this IVR method may prove useful for characterization of other liposomal products as well. C
INTRODUCTION
Liposome-formulated drugs can provide a number of compelling advantages over treatment with the unencapsulated drug, including the ability to target specific cells or tissues, promote intracellular uptake, improve the safety profile, and reduce side effects. Traditionally, the primary motivation is to modify the drug's release profile. 1, 2 Liposomes are phospholipid vesicles composed of one or more lipid bilayers surrounding an aqueous core and can vary in size ranging from approximately 20 nm to 10 :m. In addition to phospholipids, liposomes can also incorporate surfactants or cholesterol to alter the membrane rigidity, and surface modification with polyethylene glycol or antibodies to produce "stealth" liposomes or to target specific receptors, respectively. When designing a liposomal formulation, one should consider the route of delivery (e.g., inhalation, injection, infusion), the frequency of administration (e.g., once per day) and the desired in vivo release rate to ensure that drug levels remain within the "window" of adequate therapeutic effects and safety. The focus of this paper is on in vitro methodology to characterize the release rate of drug from liposomes; the two liposomal ciprofloxacin formulations used to characterize this in vitro release (IVR) method are in late stage clinical development to treat lung infections. [3] [4] [5] The in vivo release rate of drug from liposomal formulations depends on the design of the liposomal formulation, the route of delivery into the body including potential interactions between the liposomal formulation and any delivery technology that is used, and finally the interaction of the liposomes with the fluid and tissue once in the body. With respect to the formulation, the key factors affecting the release rate include the specific composition and relative proportion of the components in the vesicles (e.g., surfactants can fluidize the membrane increasing the rate of release, whereas cholesterol can have the opposite effect), the vesicle size distribution, the lamellarity of the liposomes (i.e., faster release from unilamellar liposomes), the nature of the drug (e.g., molecular weight, lipophilicity, and charge), the physical state of the drug (e.g., precipitated or in solution), and the release mechanism. 6 For inhaled liposomal formulations, the delivery device can also affect the release rate. Nebulizers used to generate aerosols have the potential to disrupt liposomes, causing an increased "burst" of drug, or modify the liposome vesicle size distribution or lamellarity, which can also affect the rate of release. 2, 7 For aerosolized liposomes, the site of deposition in the lung (e.g., bronchial airways versus alveolar space) can influence the release rate due to differences in biological fluid volume and composition. The presence of airway disease can confound the situation by influencing the site of aerosol deposition due to changes in airway dimensions, airway patency, and the ability of the patient to correctly inhale the aerosol. The drug transport rates can also be affected due to alterations in lung clearance and the composition of the lung fluid and tissue; for example, mucus and biofilms can interact with liposomes and impair mucociliary clearance and absorption.
A qualified IVR assay could be useful during product development to provide confidence in the robustness of the liposomal formulation to changes in manufacturing conditions or during storage by examining the reproducibility of a key functionality of the product-rate of drug release. A number of recent workshops have been conducted with a focus on defining the current state of IVR methodology for sustained release pharmaceutical products including the Controlled Release Society in 2007 6 and the American Association of Pharmaceutical Sciences cosponsored with both the FDA and the International Pharmaceutical Federation (FIP) in 2009. 8 Regulatory agencies have also stated that an IVR test may be useful to assess the properties of liposomal products (United States Food and Drug Association Draft Guidance on Liposome Drug Products, 2002). 9 A number of IVR methods have been evaluated for liposomeencapsulated compounds in the published literature and most of them fall into three general categories. The most straightforward are the "in situ" methods, which measure the release of drug in real time using an analytical method which can differentiate between encapsulated and released drug in the IVR sample. For drugs which fluoresce, the change in fluorescence upon release from the liposomes due to dequenching can be translated into a drug release rate. In practice, this technique has mostly been limited to model compounds such as calcein 10 and carboxyfluorescein 11 , but has also been found to be useful for doxorubicin. 12, 13 The "in situ" IVR methodology has advantages of rapid data output combined with limited sample manipulation, but, unfortunately, it is not applicable to most drugs.
A second category of IVR methods involves membrane dialysis to physically separate the released drug from the encapsulated drug in the IVR vessel. This has been performed in the standard dialysis mode, 14 the reverse dialysis mode, 15, 16 or using diffusion cells. 17 A dialysis adapter was created for use with the USP apparatus 4, which demonstrated improved discriminating power and less variability over standard and reverse dialysis techniques. 15 These dialysis-based methods are useful when the rate of release from the liposome is relatively slow compared with the time frame for the free drug to diffuse across the membrane. However, even in the presence of surfactant in the medium, the transfer of 90% of the free drug across the membrane can take 2 h. 16 Thus, these dialysis methods may not be appropriate for systems where the rate of release of the drug from the liposomes is comparable to or exceeds the rate of the drug transport through the dialysis membrane.
A third category of IVR methods involves sampling from the IVR vessel and using a second method to separate the free drug from the encapsulated drug followed by drug quantitation. The separation methods that have been used include chromatography (gel-filtration 18 or cation exchange 19 ), centrifugation or filtration. The downside to these methods has historically been the additional sample manipulation, which can lead to artifacts including additional drug release during the separation step. One advantage to the published "sample and separate" methods is that they have frequently used more physiologically relevant incubation medium to affect release; for example, plasma or serum for parenterally administered formulations.
The "sample and separate" IVR method reported in this paper utilizes bovine serum in pH 7.4 buffer as the release agent and uses centrifugal filtration devices to separate the released drug from the encapsulated drug. Serum was chosen as the release agent because there is experience using this agent with other liposomal systems and the components in serum, which are responsible for release, may also be representative of the release mechanisms in lung fluid. The main purpose of this study is to demonstrate that this IVR method is precise, reproducible and discriminatory. To this end, the sources of variability have been characterized, which would allow for subsequent method validation for the liposomal ciprofloxacin formulations evaluated in this study.
MATERIALS AND METHODS

Materials
Lipoquin R , liposomal ciprofloxacin for inhalation (CFI), empty liposomes, and free ciprofloxacin (FCI), 20 mg/mL in an acetatebuffered aqueous formulation at pH 3.3, were provided by Aradigm Corporation (Hayward, California). Pulmaquin R , dual release ciprofloxacin for inhalation (DRCFI), is an equivolume mixture of CFI and FCI. Donor Adult Bovine Serum was obtained from HyClone (Logan, Utah). Polysorbate 80 was a gift of Croda, Inc. (Edison, New Jersey). HEPES, free acid was purchased from Avantor (Center Valley, Pennsylvania). Sodium chloride was purchased from Amresco (Solon, Ohio). Sodium acetate was purchased from Sigma-Aldrich (St. Louis, Missouri). HPLC grade methanol was purchased from Fisher Scientific (Fair Lawn, New Jersey) and triethylamine (TEA) was purchased from JT Baker (Center Valley, Pennsylvania) . Nanosep centrifugal filtration devices, 10K and 30K molecular weight, were obtained from Pall Corporation (Ann Arbor, Michigan). Deionized water was used for all studies.
Preparation of Lipoquin (CFI)
The details of the preparation of Lipoquin have been reported previously. [20] [21] [22] Briefly, hydrogenated soy phosphatidylcholine and cholesterol in a 7:3 ratio (by weight) were dissolved in a t-butanol:ethanol:water mixture (49:49:2) and agitated at 70
• C for 1 h to ensure complete dissolution. This preparation was subsequently mixed 1:10 (by volume) with 500 mM ammonium sulfate and agitated at 70
• C to form multilamellar liposomes. The multilamellar vesicles were extruded through 80 nm polycarbonate filters to yield unilamellar liposomes, approximately 80 nm in diameter. The solvents were removed by diafiltration with ten volumes of 5 mM histidine, 145 mM NaCl, pH 6.0 buffer. Ciprofloxacin was added to the unilamellar liposomes at 50
• C and the preparation was agitated to facilitate active loading of drug. 21 After loading and removal of unencapsulated ciprofloxacin by diafiltration with 25 mM histidine, 145 mM NaCl, pH 6.0 buffer, greater than 99% of the ciprofloxacin was encapsulated, at a target concentration of 50 mg/mL total ciprofloxacin, expressed as ciprofloxacin hydrochloride, and 100 mg/mL total lipids. Empty liposomes were manufactured with a comparable size and composition to CFI, but without loading of drug.
EXPERIMENTAL METHODS
Recovery of Free Drug from Nanosep Centrifugal Devices and Selection of the Centrifugation Time
Nanosep centrifugation devices were used to separate the free ciprofloxacin from the liposomally encapsulated drug (Fig. 1) . In preliminary experiments, membrane filters with 10,000 and 30,000 molecular weight cutoffs were found to retain the liposomes without causing artifactual leakage of encapsulated drug. For control CFI samples, less than 1% of free drug was recovered in the filtrate, consistent with greater than 99% of the drug being encapsulated. Samples from the IVR assay were expected to contain increasing amounts of free drug after longer incubation times and so control experiments were conducted to confirm that the released "free" ciprofloxacin can be quantitatively recovered in the filtrate. Three control experiments were performed using a centrifugation time of 18 min: FCI diluted Membrane filter Figure 1 . Schematic of the use of the centrifugation filters to separate free ciprofloxacin from the IVR mixture. The IVR samples composed of free ciprofloxacin (red dots) and liposome-encapsulated ciprofloxacin (blue circles containing red dots) in serum are aliquoted (400 :L) into filtration devices and centrifuged at 10,000 rpm (8100 g) for 10 min. After centrifugation, the encapsulated drug is retained above the membrane filter, whereas the free drug in the filtrate can be subsequently quantified.
into HEPES buffered saline (HBS: 20 mM HEPES, 145 mM NaCl, pH 7.4) to determine the recovery in the absence of liposomes or serum, FCI in HBS buffer diluted 1:1 with serum to determine if the serum interferes with the recovery, and FCI and empty liposomes in HBS diluted 1:1 with serum to determine if the combination of liposomes and serum affects the recovery of free drug. All samples were further diluted 1:1 with HBS buffer before filtration recovery of free drug to improve the filterability. In all three studies, five free drug concentrations were evaluated in triplicate, 0.125, 0.5, 2.5, 6.25, and 12.5 :g/mL (to cover the range of 1%, 4%, 20%, 50%, and 100% drug release, respectively). In the third study, the amount of liposomes added was identical to the amount of liposomes present in CFI when diluted to 25 :g/mL ciprofloxacin, the standard concentration in the IVR assay, before the final 1:1 dilution with HBS buffer to aid in the filtration recovery step. The third control experiment was then repeated across a range of centrifugation times: 5, 10, 12, 15, and 18 min, to determine if a shorter centrifugation time could be used, which would still lead to acceptable and repeatable recovery of free drug.
IVR Methodology
The IVR assay is designed to measure the release of encapsulated drug, in this case ciprofloxacin, from a liposomal preparation over a period of time that is convenient for analysis; for example, 2-4 h. Exploratory studies using a range of liposomal ciprofloxacin concentrations and percent serum were conducted to identify target values which resulted in 100% release over 2-4 h incubation at 37
• C. Target values of 25 :g/mL ciprofloxacin and 50% serum were identified (data not shown). Liposomal ciprofloxacin samples, either CFI or DRCFI, were diluted to 50 :g/mL ciprofloxacin with HBS and chilled at 2
• C-8
• C before assay. The 50 :g/mL ciprofloxacin in HBS preparation was mixed one-to-one with chilled (2 • C-8
• C) bovine serum and placed in a shaking water bath [Techne, TSBS40 (Staffordshire, UK)] at 37
• C and 150 rpm to initiate the release of drug. While the T = 0 samples remained at 2
• C, the other time point samples were loaded into the 37
• C water bath. Samples, typically in triplicate, were removed periodically; for example, 30, 60, 120, and 240 min, and immediately placed in an ice-water bath to terminate any further release of encapsulated drug from the liposomes. These chilled 25 :g/mL ciprofloxacin samples (including the T = 0 samples) were then diluted 1:1 with chilled HBS to 12.5 :g/mL ciprofloxacin to reduce the concentration of serum proteins and liposomes. This step prepares the solution for filtration by reducing the load on the filter. The rate of filtration is faster for more dilute solutions and increases the volume of permeate recovered during centrifugation. An even larger dilution step would have the potential to improve the filterability even further but would increase the analytical challenges of quantifying a more dilute concentration of ciprofloxacin. Thus, the 1:1 dilution step was chosen to balance these competing considerations. To separate the "released" ciprofloxacin from the liposome-encapsulated ciprofloxacin, 400 :L of each chilled sample was transferred to a Nanosep centrifugal device and centrifuged at 10,000 rpm (8100g) for 10 min. The filtrate was removed for subsequent quantitation of the released or 'free' ciprofloxacin by HPLC. The original sample was diluted into 80% methanol to dissolve the liposomes and allow for quantitation of the total amount of ciprofloxacin by HPLC. The percent release was calculated by comparing the free drug to the total drug in each sample.
Characterization of the Accuracy and Precision of the IVR Assay
The IVR profiles for both CFI and DRCFI were characterized using the standard IVR conditions described above in the IVR Methodology. Both CFI and DRCFI were diluted with HBS buffer and bovine serum to a final concentration of 25 :g/mL ciprofloxacin and 50% serum. In order to measure the IVR method precision, six replicates of each sample were evaluated at each time point: T = 0, 30, 60, 120, and 240 min. The intermediate precision of the IVR assay was evaluated by repeating the experiment using two different analysts on each of 3 days.
Robustness: Effect of Ciprofloxacin Concentration on the IVR Profile
The target concentration after dilution was 25 :g/mL ciprofloxacin in the IVR assay for both the 50 mg/mL CFI and 35 mg/mL DRCFI formulations. Typical drug products have specification limits on the active drug concentration of ±5% and ±10% at release and on stability, respectively. Thus, acceptable product could vary by up to ±10% around the target concentration in the IVR assay, in this case, 25 :g/mL ciprofloxacin. The IVR profiles for CFI at 22.5, 25.0, and 27.5 :g/mL ciprofloxacin concentration were characterized using the standard IVR conditions described in IVR Methodology. Three replicates of each sample were evaluated at each time point: T = 0, 30, 60, 120, and 240 min. A wider range of ±25% of the target concentration (18.75, 25.0, and 31.25 :g/mL) was also evaluated for both CFI and DRCFI in order to understand the sensitivity of the IVR assay to larger variations in drug concentration.
Robustness: Effect of Percent Serum on the IVR Profile
The addition of bovine serum caused release of encapsulated drug in the IVR assay in a concentration dependent manner (data not shown). Based on exploratory studies, a value of 50% serum was selected to yield 100% release of encapsulated ciprofloxacin in a time period of 2-4 h. Additional IVR experiments were conducted to evaluate the effect of a deviation in the serum concentration by ±2% (of target) to account for typical laboratory variability; for example, due to pipetting. The IVR profiles for CFI using 49%, 50%, and 51% serum were characterized using the standard IVR conditions described in IVR Methodology. Three replicates of each sample were evaluated at each time point: T = 0, 30, 60, 120, and 240 min. A wider range of ±20% of the target value (40%, 50%, and 60% serum) was also evaluated for both CFI and DRCFI in order to understand the sensitivity of the IVR assay to larger changes in serum concentration. The initial rate of release, T 30 min − T 0 min , was defined as the amount of released drug at the 30 min time point minus that present at the initial time point.
Robustness: Effect of HBS pH on the IVR Profile
The target pH for the HBS buffer in the IVR assay is 7.4. The effect of variation in the HBS buffer pH was examined for deviations of ±0.2 pH unit: 7.2, 7.4, and 7.6. The IVR profiles for both CFI and DRCFI at 25 :g/mL ciprofloxacin were characterized using the standard IVR conditions described in IVR Methodology. Three replicates of each sample were evaluated at each time point: T = 0, 30, 60, 120, and 240 min. For CFI only, a narrower pH range of 7.3, 7.4, and 7.5 was also evaluated in order to understand the sensitivity of the IVR assay to smaller changes in the HBS buffer pH.
Robustness: Effect of Incubation Temperature on the IVR Profile
The target incubation temperature in the IVR assay is 37
• C. While the temperature of the shaking water bath can be controlled to 0.1
• C, it is important to understand the effect of temperature variations on the IVR profile. Thus, the IVR assay was repeated at 35
• C, 37
• C, and 39
• C. The IVR profiles for both CFI and DRCFI at 25 :g/mL ciprofloxacin were characterized using the standard IVR conditions, except for the variation in the incubation temperature. Three replicates of each sample were evaluated at each time point: T = 0, 30, 60, 120, and 240 min.
Robustness: Effect of Different Serum Containers on the IVR Profile
Each 500 mL serum container was subaliquoted into 10 mL plastic vials and stored frozen at −20
• C before use. These serum containers were all from one batch of serum; containers of serum from a different batch were not available when the purchase was made. It is expected that the "activity" of serum may vary across batches of serum, or even across different 500 mL containers from the same batch of serum. While this source of variability can be mitigated to some extent by ordering multiple containers of serum from a single serum lot, mixing them together to homogeneity, and freezing the serum in small aliquots in plastic vials until needed, thought must be given to how to transition from one batch to another, even if the variability across containers in one batch is acceptable. To understand the variability in serum "activity," samples of serum from four individual containers from the same serum batch, numbered 256, 257, 282, and 283, were evaluated in the IVR assay. The IVR profiles for both CFI and DRCFI at 25 :g/mL ciprofloxacin concentration were characterized using the standard IVR conditions described in the IVR Methodology. Three replicates of each sample were evaluated at each time point: T = 0, 30, 60, 120, and 240 min.
Additional Characterization of the Discriminatory Ability of the IVR Assay
While CFI and DRCFI differ in the amount of ciprofloxacin present in the formulations, the liposomal compositions are identical. To evaluate if the IVR assay can discriminate between different liposomal compositions, CFI was diluted to 12.5 mg/mL ciprofloxacin in 0.2% polysorbate 80 and equilibrated for 30 min to allow for the surfactant molecules to associate with the liposomes. The IVR assay was performed with a CFI and DRCFI control, and a further CFI control which was diluted with serum containing polysorbate 80. This second control CFI sample had an equivalent amount of surfactant to the experimental CFI sample, 0.0004% polysorbate 80 after final dilution, and thus could determine whether the presence of surfactant in the release agent at this level alters the release rate. All samples were diluted with HBS to 25 g/mL ciprofloxacin before mixing with serum. Two replicates of each sample were evaluated at each time point: T = 0, 20, 40, 60, 90, 120, and 240 min.
Ciprofloxacin Quantitation
The amount of ciprofloxacin in each sample was quantified using an HPLC method as described previously. 23 Briefly, HPLC was performed using a Nucleosil C-18 column (5 :m, 4.6 × 150 mm 2 ; Canadian Life Science (Peterborough, Ontario)) protected with a Nucleosil C-18 guard column (4 × 3.0 mm 2 ;
Phenomenex (Torrance, California)) both at 35
• C. The mobile phase was a mixture of 0.5% TEA in water, pH 3.0 and 100% methanol (83:17, v/v) and the isocratic elution was performed at a flow rate of 0.9 mL/min. Ciprofloxacin was detected at a wavelength of 277 nm.
RESULTS
Recovery of Free Drug from Nanosep Centrifugal Devices
In the absence of serum or liposomes, the recovery of free drug ranged from 102% to 106% over the 100-fold concentration range for both the 10K and 30K filtration devices, indicating that there is no hold-up of free drug across the membrane filter ( Table 1 , Group 1). In the presence of serum, the recovery was slightly lower ranging from 93% to 99% and 96% to 100% for the 10K and 30K filtration devices, respectively ( Table 1 , Group 2). In the presence of empty liposomes and serum, the mean recovery was approximately 95% for both the 10K and 30K filtration devices with an overall range of 89%-99% (Table 1 , Group 3A). The recovery of free drug using this procedure appeared to be independent of free drug concentration except for the lowest concentration condition, which had a slightly lower recovery. However, this small error would not have a meaningful impact on calculation of release values as the lowest concentration, 0.125 :g/mL, equates to only 1% release from the target 25 :g/mL value after 1:1 dilution with HBS.
The recovery of free ciprofloxacin in the presence of empty liposomes and serum was repeated for various centrifugation times, ranging from 5 to 18 min, to determine if a shorter centrifugation time would be acceptable ( Table 1 , Group 3B). The recovery was close to 95% for centrifugation times between 10 and 18 min but was slightly lower for the 5 min centrifugation time. Thus, a centrifugation time of 10 min was selected for incorporation into the standard IVR procedure. To correct for this small but reproducible loss of free drug in the filtration devices, the free drug concentration in each IVR sample is normalized by dividing by 0.949, the overall mean recovery factor using the 10 min centrifugation time.
Characterization of the Accuracy and Precision of the IVR Assay
The IVR profiles for both CFI and DRCFI were characterized using the standard IVR conditions described in IVR Methodology by two different analysts on each of three separate days (Figs. 2a and 2b) . CFI represents liposomal encapsulated ciprofloxacin, whereas DRCFI represents approximately 70% liposomal encapsulated ciprofloxacin and approximately 30% unencapsulated ciprofloxacin. The mean (±SD) time zero release values (T 0 min ) for the six IVR experiments with CFI and DRCFI were 1.1% (0.3) and 31.4% (1.1), respectively. These results are close to the expected values of <1% and approximately 30% and indicate that there is negligible additional release of free drug during the sampling and separation steps prior to drug quantitation by HPLC. Chilling the samples at 2
• C appears to adequately inhibit further release of free drug before or during the 10 min centrifugation. Furthermore, these results confirm that the centrifugation and filtration step does not damage the liposomes which could lead to significant leakage of drug.
The release of drug from CFI and DRCFI in the IVR assay proceeds in a nearly linear fashion initially, and eventually plateaus in a 2-4 h time frame at a value corresponding to complete release of drug for these liposome preparations (Figs. 2a  and 2b ). The range in mean release at the 240 min time point was 97.5%-104.7% (100.9 ± 3.1%, n = 6) for CFI and 97.1%-103.2% (100.3 ± 2.4%, n = 6) for DRCFI. In addition to having a time zero point, (T 0 min ), to characterize any burst, and a plateau value at 240 min (T 240 min ) to determine the overall extent of release, another time point was sought to represent the midpoint of release. During IVR method optimization, the 30 min time point (T 30 min ) was chosen as a "midpoint" value. In characterization studies, the rate of release, equal to the slope of the curve, at the 30 and 40 min time points was 92% and 90%, respectively, of the rate of release at the 10 min time point, suggesting that the value of T 30 min is also a reasonable estimate of the initial rate of release (data not shown). The 30 min period is also adequately long to ensure that any variability in the timing of removal of multiple samples from the incubation bath, and subsequent transfer to an ice water bath to terminate further reaction will not have a meaningful impact The recoveries represent mean ± SD of triplicate determinations. Group 1 represents recovery of ciprofloxacin diluted in HBS. Group 2 represents the recovery of ciprofloxacin in HBS diluted 1:1 with serum and then 1:1 with HBS. Groups 3A and 3B represent the recovery of ciprofloxacin in empty liposomes diluted 1:1 with serum and then 1:1 with HBS. For Groups 1, 2 and 3A, either 10K or 30K filtration devices were used. For Group 3B, the centrifugation time ranged from 5 to 18 min for the 30K centrifugation device. Release of ciprofloxacin from CFI (a) and DRCFI (b) in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37 • C for 4 h. Each value represents the mean ± SD (n = 6). There was one outlier value removed, according to predefined criteria, out of a total of 360 data points. The "No Serum Control" sample was diluted into 10 mM HEPES buffered saline, pH 7.4, without serum, and incubated at 37 • C for 4 h (n = 3 per time point).
on the release values. The range in mean release values at T 30 min was 45.3% to 50.7% (48.1 ± 2.1%, n = 6) for CFI and 59.1 to 64.8% (61.8 ± 2.3%, n = 6) for DRCFI. These values represent release of 47.4% and 44.3%, respectively, of the encapsulated drug present at T 0 min (98.9% and 68.6% for CFI and DRCFI, respectively) indicating that T 30 min is well chosen to represent the midpoint and that the rate of release from both formulations is comparable after the initial burst: While the initial rate of release is comparable for CFI and DRCFI, the IVR assay discriminates between the two formulations due to the 30% "burst"in the DRCFI formulation.
Six replicates were conducted for each sample at each time point to assess the method precision (repeatability). The replicates were very repeatable with a mean precision of 1.4%, 1.3%, 0.5%, and 0.9% RSD for the 30, 60, 120, and 240 min time points, respectively, for CFI. The mean precision for DRCFI was also comparable with values of 1.1%, 1.1%, 0.9%, and 0.7% RSD at the 30, 60, 120, and 240 min time points, respectively.
The T 0 min release values are also very repeatable, in terms of standard deviation, but because the release values are all close to zero for CFI it is not sensible to report relative standard deviations. The intermediate precision was evaluated by repeating the IVR assay using two different analysts on three days to assess the analyst-to-analyst and day-to-day variability (Figs. 2a  and 2b) . The day-to-day variability was a greater source of error than the analyst-to-analyst variability.
A control CFI sample diluted into HBS buffer alone, without serum, was incubated at 37
• C for 4 h and subjected to the same "sample and separate" methodology as for the experimental samples. Only 0.8% additional release of encapsulated drug was observed over the 4 h incubation (Fig. 2a) demonstrating that serum is required for release. This result also confirms that there is negligible nonspecific release due to the "sample and separate" methodology itself; that is, incubation for 4 h at 37
• C in pH 7.4 HBS buffer followed by the centrifugal filtration processing step. Evaluation of the effect of changes in ciprofloxacin concentration on the IVR assay. The release of (a) 22.5, 25, and 27.5 :g/mL ciprofloxacin from CFI and (b) 18.75, 25, and 31.25 :g/mL ciprofloxacin from CFI and DRCFI in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37 • C for 4 h. Each value represents the mean ± SD (n = 3). There were no outlier values out of a total of 135 data points.
Robustness: Effect of Ciprofloxacin Concentration on the IVR Profile
In order to evaluate the robustness of the assay to changes in drug concentration of ±10%, the IVR profiles for CFI at 22.5, 25.0, and 27.5 :g/mL ciprofloxacin were characterized (Fig. 3a) . All three profiles were comparable with no meaningful initial "burst," followed by a linear release for 30-60 min, which approached a plateau within 2-4 h corresponding to 100% release of drug. There was not a meaningful change in the initial release values over this concentration range with the T 30 min values varying between 43.3%-45.4%. These results suggest that the acceptable variability in drug concentration, up to ±10%, that might be expected between vials, across batches or on stability will not influence the performance in the IVR assay.
A wider range of ±25% of the target ciprofloxacin concentration (18.75, 25.0, and 31.25 :g/mL) was also evaluated for both CFI and DRCFI (Fig. 3b) . The IVR profiles again share the same features as in Figure 3a with a limited spread in the T 30 min values for CFI (40.6%-43.2%) and DRCFI (58.1%-61.8%). This suggests that the IVR assay is robust to changes in the target concentration of up to ±25%. The differences in the CFI T 30 min values between the two sets of data (40.6%-43.2% vs. 43.3%-45.4%) reflect the day-to-day assay variability. The highest ciprofloxacin concentration (31.25 :g/mL) does appear to have a slightly faster rate of release by the 60 min time point for both CFI and DRCFI but reaches the same plateau value (T 240 min ) corresponding to 100% release.
Robustness: Effect of Percent Serum on the IVR Profile
The robustness of the IVR assay to changes in serum concentration of ±2% and ±20% of the target value of 50% serum are reported in Figures 4a and 4b , respectively. As might be expected, changes in the serum concentration over both ranges had no effect on the T 0 min value or the overall extent of reaction as the plateau values all leveled off at approximately 100% release. However, higher serum concentrations resulted Figure 4 . Evaluation of the effect of changes in serum concentration on the IVR assay. After incubation at 37 • C for 4 h, the release of 25 :g/mL ciprofloxacin from (a) CFI in 49%, 50%, and 51% bovine serum and 10 mM HEPES buffered saline, pH 7.4 and (b) CFI and DRCFI in 40%, 50%, and 60% bovine serum and 10 mM HEPES buffered saline, pH 7.4. Each value represents the mean ± SD (n = 3). There were no outlier values out of a total of 135 data points. (c) The initial release rate, equivalent to the release value for T 30 min -T 0 min , is plotted versus the percent serum for both CFI and DRCFI. in a faster initial rate of release and an earlier plateau, whereas lower serum concentrations resulted in slower initial rates and a later plateau for CFI and DRCFI (Fig. 4b) . For small variations in serum of ±2% that might be expected during routine use of the IVR assay, the change in the T 30 min values was relatively small, ranging from 44.1% to 47.1% release for CFI, similar to the spread in T 30 min values due to day-to-day assay variation (section IVR Methodology). The initial reaction rate, T 30 min -T 0 min , is directly proportional to the concentration of serum used in the assay over the 40%-60% serum range (Fig. 4c) .
Robustness: Effect of HBS pH on the IVR Profile
A deviation of 0.1 pH unit in the HBS buffer from the 7.4 target value resulted in changes in the release values for CFI at T 30 min (Fig. 5a ) that exceeded the day-to-day assay variability (Fig. 2) : the range in the T 30 min values was 43.7%-55.6% with the lowest release at pH 7.3 and the highest release at pH 7.5. There was no effect on the "burst" value at T 0 min , or the plateau value of 100% release at T 240 min . However, the lower buffer pH resulted in a delay in the time to reach the plateau. This finding was also confirmed for DRCFI over the HBS buffer pH range of 7.2-7.6 with the lower HBS buffer pH (7.2) having a greater degree of impact on the initial rate of release than the higher buffer pH (7.6) (Fig. 5b) .
Robustness: Effect of Incubation Temperature on the IVR Profile
While the target IVR incubation temperature is 37.0
• C, and the shaking water bath temperature set-point can be controlled to 0.1
• C, if the assay is conducted across multiple labs using different shaking water baths the actual temperature may vary to a greater degree. Thus, it is important to understand the effect of incubation temperature on the performance of the IVR assay. The effect of a ±2
• C change in incubation temperature on the IVR profile is shown in Figure 6a for both CFI and DR-CFI. Changing the temperature did not affect the "burst" value (T 0 min ), as would be expected as these samples were not placed in the water bath, or the ultimate extent of release (T 240 min ) for either formulation. However, the rate of release was accelerated by an increase in temperature and reduced by a decrease in temperature from the target value of 37.0
• C. For CFI, the initial rate of release, T 30 min − T 0 min , was 28.5, 44.0, and 68.8% ciprofloxacin at 35
• C, respectively. For DRCFI, the initial release rate, T 30 min − T 0 min , was lower due to the "burst" at time zero: 18.4%, 28.7%, and 41.0% ciprofloxacin at 35
• C, respectively. The initial rate of release of ciprofloxacin from both the CFI and DRCFI formulations is consistent with Arrhenius kinetics over the 35
• C-39
• C temperature range as shown in Figure 6b . The values for the slopes were within 10% of each other (r 2 = 0.9999 and 0.9964 for CFI and DRCFI, respectively). An activation energy of approximately 170 kJ/mol was imputed from the mean slope values.
Robustness: Effect of Different Serum Containers on the IVR Profile
The IVR activity of serum from four different containers was evaluated for both CFI and DRCFI (Fig. 7) . All four containers of serum produced comparable IVR profiles with no significant changes in the "burst" value (T 0 min ) or the plateau value (T 240 min ) within the variability of the assay, for both CFI and DRCFI. When comparing the release at T 30 min , serum container 256 was slightly more active, whereas serum container 257 was slightly less active than containers 282 and 283, for both CFI and DRCFI. For CFI, the T 30 min values were 43.8% and 40.1% for containers 256 and 257, respectively, compared with 42.9 and 41.4 for containers 282 and 283, respectively. For DRCFI, there was a slightly greater spread in the T 30 min values with 70.3% and 60.1% recorded for containers 256 and 257, respectively, versus 65.3% and 65.2% for containers 282 and 283, respectively. The relative activity of the serum containers is in the order 256 > 282 = 283 > 257.
Additional Discrimination Across Liposomal Ciprofloxacin Formulations
CFI and DRCFI only differ in the initial "burst" of drug at T 0 min . Excluding the initial value, the rate of release of ciprofloxacin was comparable (Fig. 2a vs 2b) as would be expected because the liposomal composition in CFI and DRCFI are identical. To evaluate if the IVR assay can differentiate between different compositions that might be expected to have different release rates, 0.2% polysorbate 80 was added to 12.5 mg/mL CFI and allowed to equilibrate for 30 min before dilution into HBS and serum. After dilution, the final concentration of polysorbate 80 was only 0.0004%. The IVR profile of this formulation was substantially different from CFI and DRCFI (Fig. 8) . The "burst" (T 0 min ) increased from <1% (c.f. CFI) to 29% and the remaining encapsulated drug had a much faster release rate than for the CFI and DRCFI controls with more than 90% released after 20 min (Fig. 8) . This result could not simply be explained by the presence of the surfactant in the release buffer: the IVR profiles for CFI when diluted into serum, with or without 0.0004% polysorbate 80, were comparable (Fig. 8) . The time points in this IVR experiment were not chosen to provide a complete IVR profile for the CFI sample containing surfactant-otherwise earlier time points would have been selected given its faster release profile (e.g., 5 and 10 min); but instead simply to determine whether the IVR assay can differentiate between the samples.
DISCUSSION
Numerous drugs have been evaluated in liposomes for inhalation delivery 24 and a subset has been delivered to humans using nebulizers including imaging agents, anti-asthma drugs, analgesics, immunosuppresives, cytotoxic agents, antifungals, and antimicrobials. 1, 2 There are now two inhaled liposomal products in late-stage clinical development targeting lung infections, liposomal amikacin (ARIKACE R ; Insmed (Monmouth Junction, New Jersey)) and liposomal ciprofloxacin (Pulmaquin R ; Aradigm Corporation). Our goal was to develop and qualify an IVR assay for the inhaled liposomal ciprofloxacin formulations in order to have a laboratory assay to assess a key functional aspect of the product-the rate of drug release. Therefore, the robustness of the IVR assay was investigated with respect to the variation of the key parameters of the assay: drug concentration, serum concentration, buffer pH, incubation temperature, and serum container.
For intravenously administered liposomal products, it is reasonable to use serum as a release vehicle because the liposomes will be rapidly diluted into serum in the blood stream. However, it is less clear that serum would be an appropriate release fluid for products delivered to the lung. It is thus important to understand the components in lung fluid which would likely interact with liposomes and contribute to the release of encapsulated drug. It is well recognized that lipoproteins and apolipoproteins in serum can have a destabilizing effect on Figure 7 . Evaluation of the effect of using different serum containers (#256, 257, 282, and 283) from the same serum batch on the IVR assay. The release of 25 :g/mL ciprofloxacin from CFI and DRCFI in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37 • C for 4 h is reported. Each value represents the mean ± SD (n = 3). There were no outlier values out of a total of 120 data points. Figure 8 . Evaluation of the effect of liposomal composition on the IVR assay. The release of 25 :g/mL ciprofloxacin from CFI, CFI containing 0.0004% polysorbate 80, and DRCFI in 50% bovine serum and 10 mM HEPES buffered saline, pH 7.4 after incubation at 37 • C for 4 h is reported. An additional control CFI formulation was diluted into 50% bovine serum, 0.0004% polysorbate 80, and 10 mM HEPES buffered saline, pH 7.4. Each value represents the mean (n = 2). There was one outlier value out of a total of 56 data points.
liposomes causing drug release. 11, 25 Scherphof et al. 18 report that the phosphatidylcholine in liposomes is found to rapidly associate with lipoprotein-like particles after incubation with serum and this correlates with massive destruction of the liposome structures and release of drug. Allen and Cleland 10 confirmed and expanded on that finding by suggesting that the presence of cholesterol in the liposomes may inhibit, but not eliminate, the exchange of phospholipid with high density lipoprotein. Weinstein et al. 11 studied the interaction of proteins with lipid bilayers and found that most serum proteins did not induce release of encapsulated drug, including trypsin, albumin and ovalbumin, but that all serum lipoproteins and apolipoproteins do induce rapid release. Lipoproteins and apolipoproteins are also present in lung fluid, but at about half the concentration in serum. 26 So the IVR assay should ideally incorporate those elements into the release medium. Lung fluid also contains surfactant and lipids, which may also have a contributory effect. While there are a number of simulated lung fluid preparations published in the literature, no recognized standard exists. 27 Furthermore, of the six listed preparations, only one contains lipid and none contain surfactant or lipoproteins. Confounding the situation further, there is considerable variability in the composition of the lung fluid throughout the lung, and additional variability among individuals, without even taking into account the presence of disease on lung fluid composition. Thus, there is not a straightforward choice for release vehicle which simulates the release mechanisms in the lung. Our goal was to identify a release medium that would be biological in composition, relatively homogeneous, easy to obtain, and relevant to the release mechanism in the lung. Purified lipoprotein or apolipoprotein is not easily obtained but they are both present in serum. For that reason, bovine serum was chosen as the release medium.
The studies reported in this paper demonstrate that the selected filtration devices are able to separate free ciprofloxacin from the serum and liposomes reproducibly with an efficiency of approximately 95% across a 100-fold range in ciprofloxacin concentration ( Table 1 ). The liposomes containing encapsulated ciprofloxacin are not compromised by the centrifugation and filtration process (Fig. 1) . The utility of this filtration technique may be significantly affected by the characteristics of the encapsulated agent and therefore may not be broadly applicable to other liposomal formulations. Its usefulness will need to be assessed on a formulation by formulation basis. The IVR assay, which involves incubation with bovine serum to cause release of encapsulated drug from the liposomes, was also shown to have good precision and reproducibility. The IVR profiles for our liposomal ciprofloxacin formulations are characterized by three distinct phases of release, the initial "burst" of drug (where such "burst" was designed into each formulation), followed by a nearly linear release of drug that proceeds until a majority of the drug is released (60%-80%), and then a slower release to reach a plateau value which defines the total extent of release (Fig. 2) . The IVR assay appears to be relatively robust to changes in ciprofloxacin concentration over a range of ±25% with respect to quantifying the amount of "burst," the amount of drug released after 30 min, and the extent of release (Fig. 3 ) making these parameters suitable to monitor the release properties. The IVR assay is sensitive to intentional changes in the amount of serum (±20%), with higher serum concentrations causing an increase in the release rate. However, the normal variability due to pipette technique (±2%) did not have a meaningful impact on the reproducibility of the assay (Fig. 4) .
Changes in the HBS buffer pH had an effect on the release rate greater than the day-to-day assay variations, with deviations below pH 7.4 having a greater effect than deviations above pH 7.4 (Fig. 5) . It is unclear why relatively small deviations in buffer pH of 0.2 units have a significant influence on the rate of release. While the exact mechanism is unknown, the apolipoproteins and lipoproteins in the serum likely interact with the phospholipid in the liposomes to cause release. 11 One explanation may be that a change in pH affects the charge of ionizable groups on these lipoproteins and thus modulates their affinity for the liposomes or their affinity for each other. Another explanation may be that the serum lipoproteins increase the permeability of the liposomes, without destroying their structure, and dissipates the pH gradient across their liposome bilayers. Only the neutral, uncharged ciprofloxacin molecules are able to diffuse across the liposome bilayer so the rate of release could be proportional to the fraction of neutral, uncharged ciprofloxacin molecules. It is possible that the proportion of neutral, uncharged ciprofloxacin molecules within the liposomes increases for the pH 7.6 buffer and decreases for the pH 7.2 buffer. There may be other explanations as well. Regardless of the exact mechanism causing drug release, in order to minimize this source of variability, it is essential to implement laboratory procedures to ensure that the HBS buffer pH is as close to 7.40 as practicable.
While the details of the experiments have not been reported in this paper, there was no influence of shaking speed over the range of 100-200 rpm on the IVR assay. A shaking speed of 150 rpm, representing the midpoint of this range, has been used throughout these studies. In contrast, the incubation temperature over the range of 35
• C does affect the release rate in line with Arrhenius kinetics indicating that no phase transition is taking place over this temperature range (Fig. 6) . It is unknown if the liposomes retain their structure in the presence of serum. Changes in temperature affect the diffusion rate across biological membranes for large molecules to a greater degree than for small molecules. 28 They report that the activation energy associated with diffusion of molecules within polyisobutylene increased from 33 to 75 kJ/mol as the diffusant molecular weight increased from 2 to 72 g/mol. Thus, the imputed activation energy of approximately 170 kJ/mol for ciprofloxacin which, being a larger molecule (MW 368) would require larger pores to diffuse through, is not inconsistent with this model. Other explanations are also possible. In any case, to reduce variability in the IVR assay, for example, across laboratories, it is thus essential that the temperature control of the water bath be closely calibrated and monitored.
Each 500 mL container of bovine serum was divided into 10 mL aliquots and stored frozen until the day of use. Serum samples from all four containers produced similar IVR profiles, and had comparable effect in terms of the initial rate of release, T 30 min (Fig. 7) , but there is no assurance that subsequent containers from this batch, or containers from a different batch, will not have larger differences in activity which could be problematic when transitioning from one container to the next. We plan to investigate in the future the impact of the variation in the serum batches on the IVR assay, once they become available.
For liquid aerosols produced by nebulizers, there is the potential for the aerosol droplets to dry during laboratory collection, which could disrupt the liposome vesicles, in contrast to the in vivo situation in which the droplets are unlikely to dry in the moist and humid environment of the lungs. 7 The liposomal ciprofloxacin formulations evaluated in this paper were also characterized for their stability to the nebulization process by collecting the aerosol in an SKC BioSampler that prevents the artifactual drying. 23 In addition, the residual solution in the nebulizer at the end of nebulization was analyzed. Both were shown to retain the liposome size distribution and drug encapsulation properties. The IVR profiles of these liposomal ciprofloxacin formulations were also shown to be unaffected by nebulization using three different nebulizers. 7 Thus, this IVR method may also be amenable to characterization of liposomal aerosols if they are collected by a method that does not disrupt them.
The IVR assay was also shown to be discriminating for three liposomal ciprofloxacin formulations including two that differed in the amount of 'burst' but had similar release rates (Figs. 2a vs. 2b) and one with both a different "burst" and release rate (Fig. 8) . The presence of surfactant in the latter liposomal formulation caused an increase in the amount of free drug as well as an increase in the IVR release rate; however, no change to either parameter was observed for CFI when the surfactant was added to the release medium only. While high surfactant concentrations can solubilize liposomes, at lower concentrations the surfactant can associate with the phospholipid bilayers of the liposome and lead to increased permeability without general loss of structure to the liposome. 29 This may explain the increase in release rate. The increase in "burst" at T 0 min has also been explained by either of two mechanisms: the formation of transient pores during the initial surfactant-liposome association process which allows some of the encapsulated drug to escape before the channels close, or the rupture of a subset of liposomes which results in an increase in free drug. 30 The presence of surfactant in the release medium alone had no effect on the IVR profile indicating that the surfactant concentration was too low to compromise the liposome structure or permeability. While these formulations all approach a plateau by the 2 h time point, the inclusion of a 4 h time point (T 240 min ) is to provide discrimination power for formulations having a slower release profile which may occur for liposomes with differing compositions from those reported here (unpublished data). This IVR test may also be useful to compare different batches of product or after product is aged or subjected to various stress conditions; for example, light, heat, acid, base, temperature cycling, and so on.
The pharmacokinetic profiles of CFI and DRCFI liposomal ciprofloxacin formulations have been compared in an inhalation study in healthy subjects and both were found to have a prolonged systemic uptake, with a half-life of approximately 10 h. [31] [32] [33] However, the DRCFI formulation also achieved much higher systemic levels of ciprofloxacin over the first two hours, consistent with the "burst" of 30% ciprofloxacin observed in the IVR assay. The in vivo release is longer than the release observed in the IVR assay reported here, which was by intention, so that the assay would be rapid and convenient. The IVR assay could have been designed to more closely simulate the in vivo release rate by using a lower concentration of serum, or effecting other changes to the methodology, but that was not the goal of the present study: to develop and qualify a laboratory method for routine testing during product development.
CONCLUSIONS
This study describes an accurate and precise IVR method that has been used to characterize the release of drug from two liposomal ciprofloxacin formulations undergoing evaluation in clinical trials to treat lung infections in cystic fibrosis (CF) and non-CF bronchiectasis patients. The robustness of the assay was characterized with respect to changes in: (a) drug concentration, (b) serum (releasing agent) concentration, (c) buffer pH, (d) incubation temperature, and (e) serum containers. The IVR profile provides a measurement of the initial "burst" from the liposomal formulation when it is designed to be present in the formulation (and observed following administration to humans), followed by a nearly linear release of drug initially, ultimately reaching a plateau value representing the full extent of release. Selection of a convenient time point during the initial release phase, which is 30 min in the case of these liposomal ciprofloxacin preparations, allows for comparison between different lots of product or product from various temporal stages in its shelf-life, to provide assurance that the product retains reproducible drug release characteristics. This method was discriminatory between formulations of liposomal ciprofloxacin that differed in composition. Although this IVR assay could be useful in principle for other liposomal products, its performance may be significantly affected by the characteristics of the drug and the formulation. Its usefulness will therefore need to be assessed on a formulation by formulation basis.
